Caliway Biopharmaceuticals Co., Ltd. (TPEX: 6919)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
541.00
-14.00 (-2.52%)
Sep 10, 2024, 2:59 PM CST
48.09%
Market Cap 75.43B
Revenue (ttm) 35.52M
Net Income (ttm) -622.43M
Shares Out 139.42M
EPS (ttm) -4.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 483,997
Open 562.00
Previous Close 555.00
Day's Range 529.00 - 563.00
52-Week Range 240.50 - 800.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 13, 2024

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals Co.Ltd develops small molecule drugs for medical aesthetic and inflammatory disease. The company was founded in 2012 and is based in New Taipei City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6919
Full Company Profile

Financial Performance

In 2023, Caliway Biopharmaceuticals's revenue was 38.93 million, an increase of 203.68% compared to the previous year's 12.82 million. Losses were -488.46 million, 70.7% more than in 2022.

Financial Statements

News

There is no news available yet.